Amalgamated Bank Lowers Stake in Edwards Lifesciences Co. (NYSE:EW)

Amalgamated Bank lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 1.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 118,506 shares of the medical research company’s stock after selling 1,248 shares during the period. Amalgamated Bank’s holdings in Edwards Lifesciences were worth $8,773,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in EW. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the fourth quarter worth approximately $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences during the 3rd quarter worth $32,000. Avior Wealth Management LLC raised its position in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after buying an additional 166 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $71.46 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a 50-day moving average of $72.78 and a two-hundred day moving average of $70.18. The stock has a market cap of $42.15 billion, a P/E ratio of 10.25, a P/E/G ratio of 4.82 and a beta of 1.11. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 over the last 90 days. 1.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Barclays raised their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. The Goldman Sachs Group raised their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Piper Sandler upped their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.